Steven Cohen’s Monte Rosa Therapeutics GLUE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$9.19M Buy
+770,673
New +$13.2M 0.01% 1406
2025
Q4
– Sell
-90,419
Closed -$670K – 4000
2025
Q3
$670K Buy
+90,419
New +$479K ﹤0.01% 1816
2025
Q1
– Sell
-250
Closed -$1.74K – 2233
2024
Q4
$1.74K Buy
+250
New +$1.88K ﹤0.01% 2037
2021
Q3
– Sell
-25,000
Closed -$568K – 1118
2021
Q2
$568K Buy
+25,000
New +$509K ﹤0.01% 855

Other funds holding GLUE

Steven Cohen's GLUE Position: Q3 2026 in Review

Steven Cohen opened a new position in Monte Rosa Therapeutics (GLUE) in Q3 2026: 770,673 shares worth $9.19M. The stake represents 0.01% of the portfolio and ranks #1406 among its holdings. This is a return to the name: Steven Cohen previously reported a position in GLUE as recently as Q3 2025.

Steven Cohen first reported a position in GLUE in Q2 2021 and has held it in 4 quarters since. 188 funds tracked by Wall St. Rank hold GLUE as of Q3 2026.

  • Steven Cohen held 770,673 shares of Monte Rosa Therapeutics worth $9.19M as of Q3 2026.
  • Monte Rosa Therapeutics was a new Steven Cohen position in Q3 2026.
  • Monte Rosa Therapeutics made up 0.01% of Steven Cohen's portfolio in Q3 2026, its #1406 holding.
  • Steven Cohen first reported a position in Monte Rosa Therapeutics in Q2 2021 and has held it in 4 quarters since.
  • 188 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q3 2026.

Based on Point72 Asset Management's 13F filing for Q3 2026, filed 16 Nov 2026.